| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.6M | -10.9% | +18.8% |
| SG&A Expense | $5.2M | -11.1% | +21.3% |
| Operating Income | -$14.8M | +11.0% | -19.7% |
| Net Income | -$13.3M | +11.4% | -18.2% |
| EPS (Basic) | -$0.31 | +11.4% | +38.0% |
| EPS (Diluted) | -$0.31 | +11.4% | +38.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $12.6M | -60.2% | -75.8% |
| Short-term Investments | $120.1M | +32.4% | +303.9% |
| Current Assets | $135.6M | +8.4% | +59.4% |
| Total Assets | $144.6M | -7.8% | +53.7% |
| Current Liabilities | $9.9M | +1.5% | +14.7% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$39.4M | — | — |
| Capital Expenditures | $70K | — | — |
| Investing Cash Flow | -$112.6M | — | — |
| Financing Cash Flow | $1.8M | — | — |
| Free Cash Flow | -$39.5M | — | — |
| $12.3M |
| -1.3% |
| +0.4% |
| Stockholders' Equity | $132.3M | -8.4% | +61.7% |